vs
Paychex（PAYX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Paychex的季度营收约是Revvity的1.9倍（$1.5B vs $772.1M），Paychex净利率更高（26.3% vs 12.7%，领先13.6%），Paychex同比增速更快（17.4% vs 5.9%），Paychex自由现金流更多（$382.8M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 3.8%）
Paychex是美国知名人力资源服务提供商，1971年成立，总部位于纽约州罗切斯特，面向中小微企业提供薪资管理、人力资源外包、员工福利外包等服务。目前在美欧地区拥有超100个办事处，服务约80万家薪资客户，位列《财富》500强第681位。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PAYX vs RVTY — 直观对比
营收规模更大
PAYX
是对方的1.9倍
$772.1M
营收增速更快
PAYX
高出11.5%
5.9%
净利率更高
PAYX
高出13.6%
12.7%
自由现金流更多
PAYX
多$221.0M
$161.8M
两年增速更快
RVTY
近两年复合增速
3.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $395.4M | $98.4M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 38.0% | 14.5% |
| 净利率 | 26.3% | 12.7% |
| 营收同比 | 17.4% | 5.9% |
| 净利润同比 | -4.4% | 3.9% |
| 每股收益（稀释后） | $1.10 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAYXRVTY
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.5B | $698.9M | ||
| Q2 25 | $1.4B | $720.3M | ||
| Q1 25 | $1.5B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $1.4B | $649.9M |
净利润PAYXRVTY
| Q4 25 | $395.4M | $98.4M | ||
| Q3 25 | $383.8M | $46.7M | ||
| Q2 25 | $297.2M | $53.9M | ||
| Q1 25 | $519.3M | $42.2M | ||
| Q4 24 | $413.4M | $94.6M | ||
| Q3 24 | $427.4M | $94.4M | ||
| Q2 24 | $379.9M | $55.4M | ||
| Q1 24 | $498.6M | $26.0M |
毛利率PAYXRVTY
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.3% | 53.6% | ||
| Q2 25 | 71.5% | 54.5% | ||
| Q1 25 | 73.6% | 56.5% | ||
| Q4 24 | 70.4% | — | ||
| Q3 24 | 70.3% | 56.3% | ||
| Q2 24 | 70.1% | 55.7% | ||
| Q1 24 | 72.8% | 54.6% |
营业利润率PAYXRVTY
| Q4 25 | 38.0% | 14.5% | ||
| Q3 25 | 36.3% | 11.7% | ||
| Q2 25 | 31.2% | 12.6% | ||
| Q1 25 | 47.2% | 10.9% | ||
| Q4 24 | 42.0% | 16.3% | ||
| Q3 24 | 42.7% | 14.3% | ||
| Q2 24 | 38.3% | 12.4% | ||
| Q1 24 | 46.6% | 6.8% |
净利率PAYXRVTY
| Q4 25 | 26.3% | 12.7% | ||
| Q3 25 | 25.7% | 6.7% | ||
| Q2 25 | 21.5% | 7.5% | ||
| Q1 25 | 35.4% | 6.4% | ||
| Q4 24 | 32.3% | 13.0% | ||
| Q3 24 | 33.4% | 13.8% | ||
| Q2 24 | 30.2% | 8.0% | ||
| Q1 24 | 35.7% | 4.0% |
每股收益（稀释后）PAYXRVTY
| Q4 25 | $1.10 | $0.86 | ||
| Q3 25 | $1.06 | $0.40 | ||
| Q2 25 | $0.83 | $0.46 | ||
| Q1 25 | $1.43 | $0.35 | ||
| Q4 24 | $1.14 | $0.77 | ||
| Q3 24 | $1.18 | $0.77 | ||
| Q2 24 | $1.05 | $0.45 | ||
| Q1 24 | $1.38 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $919.9M |
| 总债务越低越好 | $5.0B | — |
| 股东权益账面价值 | $3.9B | $7.3B |
| 总资产 | $16.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.28× | — |
8季度趋势，按日历期对齐
现金及短期投资PAYXRVTY
| Q4 25 | $1.5B | $919.9M | ||
| Q3 25 | $1.7B | $931.4M | ||
| Q2 25 | $1.7B | $991.8M | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $2.0B | ||
| Q1 24 | $1.7B | $1.7B |
总债务PAYXRVTY
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $798.6M | — | ||
| Q1 24 | — | — |
股东权益PAYXRVTY
| Q4 25 | $3.9B | $7.3B | ||
| Q3 25 | $4.0B | $7.4B | ||
| Q2 25 | $4.1B | $7.6B | ||
| Q1 25 | $4.1B | $7.6B | ||
| Q4 24 | $3.9B | $7.7B | ||
| Q3 24 | $3.9B | $7.9B | ||
| Q2 24 | $3.8B | $7.9B | ||
| Q1 24 | $3.7B | $7.8B |
总资产PAYXRVTY
| Q4 25 | $16.5B | $12.2B | ||
| Q3 25 | $16.7B | $12.1B | ||
| Q2 25 | $16.6B | $12.4B | ||
| Q1 25 | $11.2B | $12.4B | ||
| Q4 24 | $10.6B | $12.4B | ||
| Q3 24 | $10.5B | $12.8B | ||
| Q2 24 | $10.4B | $13.4B | ||
| Q1 24 | $13.0B | $13.4B |
负债/权益比PAYXRVTY
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.25× | — | ||
| Q2 25 | 1.20× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $444.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $382.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 25.5% | 21.0% |
| 资本支出强度资本支出/营收 | 4.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.13× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $2.0B | $509.4M |
8季度趋势，按日历期对齐
经营现金流PAYXRVTY
| Q4 25 | $444.9M | $182.0M | ||
| Q3 25 | $718.4M | $138.5M | ||
| Q2 25 | $343.8M | $134.3M | ||
| Q1 25 | $716.0M | $128.2M | ||
| Q4 24 | $295.0M | $174.2M | ||
| Q3 24 | $546.1M | $147.9M | ||
| Q2 24 | $221.7M | $158.6M | ||
| Q1 24 | $671.7M | $147.6M |
自由现金流PAYXRVTY
| Q4 25 | $382.8M | $161.8M | ||
| Q3 25 | $662.5M | $120.0M | ||
| Q2 25 | $283.3M | $115.5M | ||
| Q1 25 | $667.3M | $112.2M | ||
| Q4 24 | $248.0M | $149.8M | ||
| Q3 24 | $510.5M | $125.6M | ||
| Q2 24 | $180.4M | $136.6M | ||
| Q1 24 | $631.0M | $129.7M |
自由现金流率PAYXRVTY
| Q4 25 | 25.5% | 21.0% | ||
| Q3 25 | 44.4% | 17.2% | ||
| Q2 25 | 20.5% | 16.0% | ||
| Q1 25 | 45.5% | 16.9% | ||
| Q4 24 | 19.4% | 20.5% | ||
| Q3 24 | 39.9% | 18.4% | ||
| Q2 24 | 14.4% | 19.7% | ||
| Q1 24 | 45.2% | 20.0% |
资本支出强度PAYXRVTY
| Q4 25 | 4.1% | 2.6% | ||
| Q3 25 | 3.7% | 2.6% | ||
| Q2 25 | 4.4% | 2.6% | ||
| Q1 25 | 3.3% | 2.4% | ||
| Q4 24 | 3.7% | 3.4% | ||
| Q3 24 | 2.8% | 3.3% | ||
| Q2 24 | 3.3% | 3.2% | ||
| Q1 24 | 2.9% | 2.7% |
现金转化率PAYXRVTY
| Q4 25 | 1.13× | 1.85× | ||
| Q3 25 | 1.87× | 2.97× | ||
| Q2 25 | 1.16× | 2.49× | ||
| Q1 25 | 1.38× | 3.03× | ||
| Q4 24 | 0.71× | 1.84× | ||
| Q3 24 | 1.28× | 1.57× | ||
| Q2 24 | 0.58× | 2.87× | ||
| Q1 24 | 1.35× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAYX
| Management Solutions | $1.2B | 78% |
| Peo And Insurance Solutions | $336.9M | 22% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
